Related Experiment Video
Updated: Aug 25, 2026
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
S100A5: a marker of recurrence in WHO grade I meningiomas
1Department of Neurosurgery, Erasmus Univesity Hospital, Brussels, Belgium.
Abstract:
Some WHO grade I intracranial meningiomas resected from the same sites and with the same quality of resection (Simpson's grading scale) recur, while others do not. The reasons for this variability in occurrence of recurrence have not yet been determined. We therefore investigated the prognostic recurrence value of seven biological markers on a series of completely resected WHO grade I meningiomas. For this purpose, we analysed a series of 33 WHO grade I meningiomas totally resected between 1980 and 1990 (a follow-up of 10 years), including 14 cases of recurrence. The fixed tumour material from each meningioma was submitted to histochemical analyses targeting galectin-3 and its binding sites, the S100A5, S100A6 and S100B proteins, and cathepsin-B and -D. The levels of expression were assessed semi-quantitatively (in terms of the staining intensity and the labelling index) and submitted to uni- and multivariate analyses. Of all the markers investigated, only S100A5 expression can be associated with any significant prognostic value in the matter of recurrence. More particularly, the meningiomas with high levels of S100A5 staining intensity either did not recur, or recurred later than those with a low immunopositive S100A5 intensity (P = 0.004). Cox regression analyses demonstrated that this latter marker was associated with significant prognostic values independent of the patients' ages. Furthermore, the combination of the patients' ages and S100A5 staining intensity permitted the identification of a group with a particularly high risk of recurrence, that is, the patients younger than 55 and with meningiomas exhibiting low S100A5 intensities (P = 0.001). In conclusion, the S100A5 protein could play a role in the recurrence of totally resected WHO grade I meningiomas.
Insights
Recurrence of WHO grade I meningiomas varies. High S100A5 protein expression indicates a lower risk of recurrence, especially when combined with patient age, identifying high-risk individuals.
Area of Science:
- Neurosurgery
- Oncology
- Pathology
Background:
- WHO grade I intracranial meningiomas can recur despite complete resection.
- The variability in recurrence rates is not fully understood.
- Identifying prognostic markers is crucial for predicting meningioma recurrence.
Purpose of the Study:
- To investigate the prognostic value of seven biological markers in predicting recurrence of completely resected WHO grade I meningiomas.
- To determine if S100A5 protein expression levels correlate with meningioma recurrence risk.
Main Methods:
- Analysis of 33 completely resected WHO grade I meningiomas with a 10-year follow-up.
- Histochemical analysis of galectin-3, S100A5, S100A6, S100B, cathepsin-B, and cathepsin-D expression.
- Semi-quantitative assessment of marker expression and uni- and multivariate statistical analyses, including Cox regression.
Main Results:
- S100A5 protein expression was the only marker significantly associated with recurrence.
- Higher S100A5 staining intensity correlated with no or delayed recurrence (P = 0.004).
- A combination of younger patient age (<55) and low S100A5 intensity identified a high-risk group for recurrence (P = 0.001).
Conclusions:
- S100A5 protein expression is a significant prognostic marker for recurrence in completely resected WHO grade I meningiomas.
- S100A5 levels, particularly in conjunction with patient age, can help stratify recurrence risk.
- Further research into the role of S100A5 in meningioma pathogenesis is warranted.
